ARDELYX, INC. Long-Term Debt, Maturity, Year Five
ARDELYX, INC. (ARDX) had Long-Term Debt, Maturity, Year Five of $2.89 million as of 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2023-03-02
- 2022-12-31: Long-Term Debt, Maturity, Year Five $2.89M.
- 2018-09-30: Long-Term Debt, Maturity, Year Five $24.89M.
- 2018-06-30: Long-Term Debt, Maturity, Year Five $24.89M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2022-12-31 | $2.89M 10-K · filed 2023-03-02 |
| 2018-09-30 | $24.89M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $24.89M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |